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The adaptive cytotoxic T lymphocyte (CTL)-mediated immune response is critical for clear-
ance of many viral infections. These CTL recognize naturally processed short viral antigenic
peptides bound to human leukocyte antigen (HLA) class I molecules on the surface of
infected cells. This specific recognition allows the killing of virus-infected cells. The T cell
immune T cell response to Chikungunya virus (CHIKV), a mosquito-borne Alphavirus of the
Togaviridae family responsible for severe musculoskeletal disorders, has not been fully
defined; nonetheless, the importance of HLA class I-restricted immune response in this
virus has been hypothesized.
Methodology/Principal findings
By infection of HLA-A*0201-transgenic mice with a recombinant vaccinia virus that encodes
the CHIKV structural polyprotein (rVACV-CHIKV), we identified the first human T cell epi-
topes from CHIKV. These three novel 6K transmembrane protein-derived epitopes are
presented by the common HLA class I molecule, HLA-A*0201. One of these epitopes is pro-
cessed and presented via a complex pathway that involves proteases from different subcel-
lular locations. Specific chemical inhibitors blocked these events in rVACV-CHIKV-infected
cells.
Conclusions/Significance
Our data have implications not only for the identification of novel Alphavirus and Togaviri-
dae antiviral CTL responses, but also for analyzing presentation of antigen from viruses of
different families and orders that use host proteinases to generate their mature envelope
proteins.







Citation: Lorente E, Barriga A, Garcı́a-Arriaza J,
Lemonnier FA, Esteban M, López D (2017)
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Author summary
The arboviral pathogen Chikungunya virus (CHIKV) is a serious threat to global health,
and is considered a priority re-emerging virus. This pathogen causes acute febrile infec-
tion in patients, leading to debilitating arthralgia and arthritis. In recent years, CHIKV
has spread quickly in tropical and subtropical countries, causing outbreaks of more severe
forms of the disease than previously reported. The nature and function of the T cell
immune response, critical for clearance of viral infections, is largely unknown during
acute and chronic CHIKV disease and their association with rheumatic disorders. In this
study, we identified the three first CHIKV epitopes recognized by human T cells. We stud-
ied how one of these epitopes is generated in virus-infected cells, a process that involves
the sequential proteolytic activity of several proteases at distinct subcellular locations. We
postulate that this process could have broad implications when applied to other viral
proteins.
Introduction
The mosquito-borne Chikungunya virus (CHIKV), a member of the Alphavirus genus of the
Togaviridae family, causes an acute febrile infection in patients that leads to debilitating
arthralgia and arthritis. Identified in the former Tanganyika territory in 1952 [1–3], this arbo-
viral pathogen caused numerous epidemics in Africa and Asia from the 1960s–1980s [4, 5].
Following several decades of relative inactivity, CHIKV re-emerged in 2005 to cause an explo-
sive epidemic in the Indian Ocean area, mainly on Reunion Island. In this French overseas
department, the outbreak affected about half of its 700,000 inhabitants, with more than 250
deaths [5]. In 2006, several million people were infected by this virus in another large outbreak
in India [6]. In recent years, this infectious disease has spread quickly from Africa and Asia to
the Americas [7], causing outbreaks in tropical and subtropical countries of more severe forms
than previously reported [8,9]. Morbidity due to CHIKV infection is a serious threat to global
health and this virus is considered a priority emerging pathogen [10].
CHIKV is an enveloped virus with a positive-sense, single-stranded RNA genome that
encodes two large polyproteins [11]. The nonstructural P1234 precursor is autocatalytically
processed by the C-terminal domain of the nonstructural protein 2 (nsP2) and releases the
four multifunctional nsP proteins. In contrast, in maturation of the structural polyprotein,
viral and host proteases are both involved in producing capsid, E1, E2, and E3 envelope and
6K transmembrane proteins [11].
Although the immune mechanisms involved in CHIKV disease are not fully understood,
CHIKV-infected humans show CD8+ T lymphocyte responses in early disease stages [12]; a
large percentage of these activated CD8+ T cells can be detected more than 7 weeks postinfec-
tion in patient blood samples [13]. The nature and function of CD8+ T cells during acute and
chronic CHIKV infection is largely unknown, as is their association with rheumatic disorders.
Although the importance of the HLA class I-restricted immune response has been hypothe-
sized [14], to date, no human T cell epitope has been described in CHIKV infection.
In cellular immunity, CD8+ T lymphocytes recognize short viral peptides exposed at the
membrane of infected cells [15]. Most of these epitopes are generated by proteolytic degrada-
tion of the fraction of newly synthesized viral proteins whose sequence or folding are in some
way defective (defective ribosomal products; DRiP) and are thus degraded immediately by the
combined action of proteasomes and other cytosol degradative peptidases [16]. The antigen
processing products are translocated to the endoplasmic reticulum (ER) lumen by transporters
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associated with antigen processing (TAP), where N-terminal trimming by the ER aminopepti-
dase (ERAP) is frequently necessary [17,18]. Some of these final peptides might bind the
human histocompatibility complex (human leukocyte antigen; HLA) class I heavy chain and
β2-microglobulin. The stable trimolecular peptide-HLA-β2-microglobulin complexes are then
exported to the cell surface for cytotoxic T lymphocyte (CTL) recognition [15]. In addition to
this classical antigen processing pathway, several alternative routes have been described that
contribute to endogenous HLA class I-restricted antigen processing (reviewed in [19]). During
maturation of the viral structural polyprotein, the short CHIKV 6K transmembrane protein is
efficiently cleaved by the host ER signal peptidase, rendering it a possible source of viral epi-
topes via alternative pathways. To search for CHIKV 6K protein T cell epitopes, we infected
HLA-A0201-transgenic mice with a recombinant vaccinia virus that encodes the CHIKV
structural polyprotein; we identified three epitopes presented by the HLA class I molecule, one




H-2 class I knockout HLA-A0201-transgenic mice [20], a versatile animal model for the
study of viral and cancer antigen processing and presentation by the human major histocom-
patibility complex, were bred in the animal facilities at Centro Nacional de Microbiologı́a,
Instituto de Salud Carlos III, in strict accordance with the recommendations in the Guide for
the Care and Use of Laboratory Animals of the Spanish Comisión Nacional de Bioseguridad of
the Ministerio de Medio Ambiente y Medio Rural y Marino (accreditation n˚ 28079-34A).
The protocol was approved by the Research Ethics and Animal Welfare Committee of the Car-
los III Health Institute (permit n˚: PI-283). All surgery was performed under isoflurane anes-
thesia, and all efforts were made to minimize suffering.
Cell lines
The murine cell line RMA-S (TAP negative) transfected with HLA-A0201 α1α2 domains,
and the mouse H-2Db α3 transmembrane and cytoplasmic domains have been described [21].
The cell line was cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum
(FBS) and 5 μM β-mercaptoethanol (β-ME).
Construction of recombinant VACV-CHIKV (rVACV-CHIKV)
A vaccinia virus (VACV) Western Reserve (WR) strain expressing the CHIKV structural
genes (rVACV-CHIKV) was constructed by inserting the capsid (CP), E3, E2, 6K and E1
structural genes of CHIKV clone LR2006-OPY1 into the TK locus of the WR genome [22].
The rVACV-CHIKV virus expresses the same CHIKV structural genes as those in the reported
MVA-CHIKV vaccine candidate [22]. The WR strain used as the parental vector to generate
rVACV-CHIKV is an optimized attenuated WR with deletions in the vaccinia immunomodu-
latory genes A48R, B19R and C11R (manuscript in preparation). CHIKV structural gene
expression is under the transcriptional control of the viral synthetic early/late promoter. The
rVACV-CHIKV virus was generated, grown in primary chicken embryo fibroblast cells and
purified through two 36% (w/v) sucrose cushions. Correct CHIKV gene insertion was con-
firmed by PCR and sequencing, and correct CHIKV protein expression was analyzed by west-
ern blot. rVACV-CHIKV was free of contamination with mycoplasma, bacteria or fungi.
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Synthetic peptides
Peptides were purchased from Biomatik (Cambridge, Ontario, Canada). The correct molecular
mass and composition of the peptides at>90% purity was established by quadrupole ion trap
micro-high performance liquid chromatography (HPLC).
Inhibitors
Brefeldin A (BFA) and all protease inhibitors were purchased from Sigma-Aldrich (Saint
Louis, MO, USA), with the exception of lactacystin (from Dr. E.J. Corey, Harvard University,
Cambridge, MA, USA), leupeptin (Amersham, Little Chalfont, Bucks., UK), pepstatin (Boeh-
ringer Mannheim, Mannheim, Germany), and Z-VAD-FMK (Enzyme System Products, Liv-
ermore, CA, USA). The specificity of inhibitors used is summarized in Table 1.
HLA ligand prediction
SYFPEITHI software (http://www.syfpeithi.de/Scripts/MHCServer.dll/EpitopePrediction.
htm) was used to predict HLA-A0201-specific ligands of the 61-residue CHIKV 6K protein.
HLA/peptide stability assays
Two synthetic peptides were used as positive and negative controls in complex stability assays,
VACV A10L688-696 (ILDRIITNA, HLA-A
0201-restricted) [23] and CMV pp657-15 (RCPE-
MISVL, HLA-C01-restricted) [24], respectively. HLA-A0201 RMA-S transfectants were
incubated in RPMI 1640 medium with 10% heat-inactivated FBS (16 h, 26˚C). Cells were
washed and incubated in the same medium (2 h, 26˚C) with different peptide concentrations,
further incubated (2 h, 37˚C), and collected for flow cytometry. HLA levels were measured
using the PA2.1 monoclonal antibody (anti-HLA-A02; Abnova, Taipei, Taiwan), as described
Table 1. General specificity of inhibitors used in this study.
Inhibitor a Abbreviation Specificity Reference Concentration
Lactacystin LC Proteasome chymotryptic and tryptic activities [38,39] 10 μM
Chloroquine CQ Lysosomotropic agent [60,61] 50 μM
Brefeldin BFA Vesicle transport [31,32] 5 μg/ml
1–10 Phenanthroline PHE All metalloproteases and caspase-1 [35,62] 50 μM
Leupeptin LEU Trypsin-like proteases and cysteine proteases [34] 100 μM
Puromycin PURO Cytosol alanyl aminopeptidase and lysosomal
dipeptidyl-peptidase II
[63] 0.5 μg/ml
Pepstatin PEPST Aspartic proteases [34,35] 100 μM
E64 E64 Cysteine proteases C1 [33] 100 μM
Leucinthiol Leu-SH Metallo-aminopeptidases including ERAP [40] 30 μM
Diazoacetyl-D,L-norleucine methyl ester DANLME Aspartic proteases A1 [64] 100 μM
Decanoyl-Arg-Val-Lys-Arg-chloromethylketone dec-RVKR Furin and other proprotein convertases [65] 100 μM
1,3-di-(N-benzyloxycarbonyl-Leu-Leu)amino
acetone
Z-LL2 Signal peptide peptidase [66,67] 100 μM
Ethylenediaminetetraacetic acid EDTA Most metallopeptidases and some cysteine proteases [68] 100 μM
Phenylmethane sulfonylfluoride PMSF Serine peptidases [36] 1mM
Soybean Kunitz trypsin inhibitor SBTI Trypsin and to a lesser extent chymotrypsin and
plasmin
[69] 100 μg/ml
Bestatin BEST Most of metallo-aminopeptidases [35] 50 μM
Carbobenzoxy-Val-Ala-Asp-[O-methyl]-
fluoromethylketone
Z-VAD Caspases [70] 100 μM
a All inhibitors, except Z-VAD that block apoptosis, prevent proteolytic degradation in cellular extracts as measured in reference [26].
https://doi.org/10.1371/journal.pntd.0006036.t001
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[25]. Samples were acquired on a FACSCanto flow cytometer (BD Biosciences, San Jose, CA,
USA) and analyzed with FlowJo software (TreeStar Inc, Ashland, OR, USA). The fluorescence
index (FI) was calculated as the ratio of the mean channel fluorescence of the sample to that
of control cells incubated without peptides. Peptide binding was also expressed as the EC50,
which is the molar concentration of peptides that produces 50% maximum fluorescence in a
concentration range between 0.001 and 100 μM.
Generation of CD8+ T cell lines
Polyclonal CHIKV 6K peptide-monospecific CD8+ T cell lines were generated by immunizing
transgenic mice with 107 plaque-forming units (PFU) of rVACV-CHIKV [26]. Splenocytes
from immunized mice were restimulated in vitro with mitomycin C-treated spleen cells pulsed
with 10−6 M peptide and cultured Minimum Essential Medium (Alpha modification; α-MEM)
with 10% FBS, 10−7 M peptide and 5 μM β-ME. Recombinant human interleukin-2 used for
long-term propagation of peptide-specific CD8+ T cell lines was generously provided by Hoff-
mann-LaRoche (Basel, Switzerland).
Bone marrow-derived dendritic cells
Freshly prepared bone marrow cells were cultured in 200 U/ml GM-CSF (granulocyte-macro-
phage colony-stimulating factor; PeproTech, London, UK), which was renewed on days 3 and
6. After 7 days, nonadherent cells with a typical dendritic cell (DC) morphology and a myeloid
DC phenotype (MHC class II+, CD11c+, CD8−) were collected as described [27].
IFNγ-secreting cell detection by intracellular cytokine staining (ICS)
ICS assays to detect recognition of peptide-pulsed or infected DC from HLA-A0201-trans-
genic mice by polyclonal CTL cell lines were performed as reported [28]. Briefly, CD8+ T cell
lines were stimulated (4 h) in the presence of 5 μg/ml BFA and of target DC previously infected
with VACV-WR strain or rVACV-CHIKV (16 h). Cells were then incubated with FITC-conju-
gated anti-CD8 monoclonal antibody (mAb; ProImmune, Oxford, UK; 30 min, 4˚C), fixed
with Intrastain kit reagent A (DakoCytomation, Glostrup, Denmark), and incubated with phy-
coerythrin (PE)-conjugated anti-interferon (IFN)γ mAb (BD PharMingen, San Diego, CA,
USA) in Intrastain kit permeabilizing reagent B (30 min, 4˚C). Events were acquired and ana-
lyzed as for MHC/peptide stability assays.
When protease inhibitors were used, all drugs were added 15 min before the virus and
maintained at a 2-fold higher concentration during the 1-h adsorption period than during
infection. After washing the virus inoculum, inhibitors were maintained at indicated concen-
trations for individual experiments. The inhibitors were not toxic at these concentrations, as
they did not affect antigen presentation by the VACV D12I251-259-specific CD8
+ T cell line.
Statistical analysis
To analyze statistical significance, an unpaired Student t test was used. P values<0.05 were
considered significant.
Results
Selection of potential candidate HLA-A*0201 epitopes from CHIKV 6K
protein
The epitope prediction tool SYFPEITHI, a reverse immunology algorithm for MHC ligand
motifs [29], was used to identify possible candidate HLA-A0201-binding peptides from
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CHIKV 6K protein. The five nonamers and three decamers ranked as potential HLA-A0201
ligands (score >20) are depicted in Fig 1.
To study the binding ability of the eight predicted peptides to the HLA-A0201 molecule,
we performed MHC-peptide complex stability assays using HLA-A0201-transfected, TAP-
deficient RMA-S cells. Four peptides (6K31-39, 6K37-46, 6K45-54, 6K51-59) were bound to the
HLA-A02:01 class I molecules (Fig 2), with EC50 values in the range commonly found among
natural high-affinity ligands such as the VACV A10L HLA-A0201 epitope. In contrast, HLA
affinity was substantially lower for 6K22-30 and 6K22-31 peptides, and both were considered
medium-affinity ligands (Fig 2). 6K21-29 peptide binding to HLA-A
02:01 was residual, with a
EC50 value>200 μM (Fig 2). Stable numbers of HLA-peptide surface complexes were not
detected with the 6K28-36 peptide (Fig 2). These data suggest that most of these peptides could
be presented by the HLA-A02:01 molecule in CHIKV-infected cells.
Identification of three CHIKV 6K-derived HLA-A*0201 epitopes
In contrast to HLA-B0702 transgenic mice, in which strong ex vivo VACV-specific T cell
responses were detected [28], peptide-specific IFNγ-secreting cells from VACV-immunized
HLA-A0201 transgenic mice were usually detected only after in vitro stimulation. The cause
of these differences is unclear, especially as both transgenic mouse types were generated in the
same laboratory [20,30].
From rVACV-CHIKV-immunized HLA-A0201 transgenic mice, we produced polyclonal
CTL lines monospecific for each of seven CHIKV 6K peptides with stable numbers of HLA-
peptide surface complexes detected in MHC-peptide complex stability assays (Table 2). The
CTL lines stimulated with three of the four HLA-A0201 high-affinity peptides (6K31-39,
6K45-54, 6K51-59) specifically recognized peptide-pulsed DC (Fig 3). There was no specific
recognition of peptide-pulsed cells by the other four CHIKV 6K peptides (6K21-29, 6K22-30,
6K22-31, and 6K37-46; Table 2); this lack of response was confirmed using several immunization
and in vitro stimulation protocols (not shown).
These data indicated that CHIKV 6K31-39, 6K45-54, and 6K51-59 peptides are HLA-A
0201-
restricted CTL epitopes, and were recognized simultaneously as part of the memory response to
rVACV-CHIKV. The small (61-residue) CHIKV 6K protein thus contains at least three distinct
HLA-A0201-restricted epitopes, two of which overlap partially.
Fig 1. Location of potential HLA-A*0201-restricted ligands from CHIKV 6K protein. Sequence and scheme
of CHIKV 6K protein, with the position of eight potential HLA-A*0201 ligands predicted by the SYFPEITHI
software.
https://doi.org/10.1371/journal.pntd.0006036.g001
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Endogenous processing of the CHIKV 6K51-59 epitope
As the three CHIKV 6K viral epitopes derive from the same 6K protein, we studied the CD8+
CTL line specific for the CHIKV 6K51-59 epitope as a representative of antigen processing of
this viral protein. The CHIKV 6K51-59 epitope-specific CD8
+ CTL line specifically recognized
rVACV-CHIKV- but not wild type VACV-infected cells, while another T cell line specific for
VACV D12I peptide 251–259 recognized both infected cells (Fig 4).
Fig 2. HLA-A*0201 stabilization with CHIKV 6K synthetic peptides. The stability of HLA-A*0201-peptide complexes on the surface of
transfected RMA-S cells was measured by flow cytometry. Left, the indicated peptides were used at 200 μM. The CMV pp65 and VACV A10L
peptides were used as negative and positive controls, respectively. The mAb PA2.1 was used for staining. The results, calculated as fluorescence
indexes, are shown as the mean ± SD of four independent experiments (*** p <0.001; ** p <0.01; * p <0.05 vs. negative or positive peptide
controls are represented as white or black asterisks, respectively). Right, titration curves for the indicated synthetic peptides with HLA-A*0201.
Results are shown as mean values from four independent experiments. Calculated EC50 values (μM; mean ± SD) are shown in the right panel
insert.
https://doi.org/10.1371/journal.pntd.0006036.g002
Table 2. Summary of CHIKV 6K peptide recognition by specific CD8+ T cell lines.
CHIKV peptide Sequence HLA-A*0201 Affinity values a CTL Line b
6K 21–29 QALIPLAAL > 200 -
6K 22–30 ALIPLAALI 33 ± 28 -
6K 22–31 ALIPLAALIV 21 ± 20 -
6K 28–36 ALIVLCNCL No binding N.D.
6K 31–39 VLCNCLRLL 5 ± 3 +
6K 37–46 RLLPCCCKTL 8 ± 6 -
6K 45–54 TLAFLAVMSV 1 ± 0.5 +
6K 51–59 VMSVGAHTV 9 ± 1 +
a Data are expressed as EC50 (μM) ± SD
b Measured as IFNγ secretion using ICS assays;
N.D., not done
https://doi.org/10.1371/journal.pntd.0006036.t002
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CHIKV 6K is a structural protein necessary both for virus budding and entry, which is
incorporated in small amounts into the virion [11]. As rVACV-CHIKV expresses the five
structural proteins of the pathogen, we cannot rule out the presence of CHIKV virus-like
particles and possible exogenous antigen presentation. To test whether the CHIKV 6K51-59
Fig 3. CHIKV 6K peptide specificity of HLA-A*0201-restricted CD8+ T cell lines. Mouse HLA-A*0201+
DC pre-pulsed with 10−6 M of indicated CHIKV 6K synthetic peptide were analyzed by ICS for CD8+ T cell
activation with CHIKV peptide-specific CD8+ T cells from HLA-A*0201-transgenic mice immunized with
rVACV-CHIKV and restimulated in vitro with the appropriate CHIKV 6K synthetic peptide. Graph data shown
as mean ± SD of four independent experiments (*** P <0.001). Representative ICS panels with non-specific
or CHIKV peptide-specific CD8+ T cell lines are depicted beneath the graphs. The percentages of IFNγ-
expressing CD8+ T cells are indicated in each dot plot.
https://doi.org/10.1371/journal.pntd.0006036.g003
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Fig 4. Recognition of infected HLA-A*0201+ dendritic cells by CHIKV 6K51-59- or VACV D12I251-259-
specific CD8+ T cells. Mouse HLA-A*0201+ DC infected with VACV or rVACV-CHIKV (m.o.i. 10 pfu/cell; 5 h)
were used in an ICS assay to test for recognition by CHIKV 6K51-59- or VACV D12I251-259-specific CD8
+ T cell
lines. Graph data shown as mean ± SD of four independent experiments (** P <0.01). Below the graphs,
representative ICS panels for CHIKV 6K51-59- or VACV D12I251-259-specific CD8
+ T cell lines are shown. The
percentages of IFNγ-expressing CD8+ T cells are indicated in each dot plot.
https://doi.org/10.1371/journal.pntd.0006036.g004
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HLA-A0201-restricted epitope requires endogenous processing, we analyzed its presentation
in the presence of BFA. Brefeldin A blocks class I export beyond the cis-Golgi compartment
[31,32], preventing surface expression of newly assembled HLA class I-peptide complexes of
endogenous origin (Table 1 summarizes the specificity of all inhibitors used). BFA addition
during infection completely inhibited specific IFNγ secretion by the CHIKV 6K51-59 epitope-
specific CD8+ T cell line (Fig 5), which demonstrated that this epitope was generated from
CHIKV 6K protein endogenously processed in rVACV-CHIKV-infected cells. We also
observed complete inhibition of specific IFNγ secretion by the VACV D12I251-259 epitope-spe-
cific CD8+ T cell line (Fig 5).
A furin-like protease inhibitor specifically blocks CHIKV 6K51-59 epitope
recognition
To study the antigen processing pathways involved in endogenous generation of the CHIKV
6K51-59 epitope, we performed ICS assays with several specific protease inhibitors on rVACV-
CHIKV-infected cells. We tested E64 [33], leupeptin (LEU) [34], pepstatin (PEPST) [34,35],
1,10-phenanthroline (PHE), and phenylmethylsulfonyl fluoride (PMSF) [36] inhibitors, as
they are specific for different protease families and cover a wide range of protease classes
(Table 1). None of these inhibitors affected specific recognition of rVACV-CHIKV-infected
target cells by the CHIKV 6K51-59-specific CD8
+ T cell line (Fig 6). The enzymes inhibited by
these drugs are thus not involved in generation of this epitope.
Fig 5. BFA effect on recognition of CHIKV 6K51-59 or VACV D12I251-259 viral epitopes. Mouse HLA-A*0201
+ DC infected as in Fig 4 were treated
with BFA. An ICS assay was used to test for recognition by CHIKV 6K51-59- or VACV D12I251-259-specific CD8
+ T cell lines. Graph data are expressed
as percentage of inhibition as by ICS in the presence of BFA (mean ± SD of four independent experiments; *** P <0.001 vs. respective
rVACV-CHIKV-infected cells). Representative ICS panels with CHIKV 6K51-59- or VACV D12I251-259-specific CD8
+ T cell lines are shown.
https://doi.org/10.1371/journal.pntd.0006036.g005
First HLA class I epitopes from Chikungunya virus
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0006036 October 30, 2017 10 / 21
We also tested specific inhibitors of several cellular proteases, most of which were not rele-
vant for antigen processing of the CHIKV 6K51-59 viral epitope (Fig 7). In contrast, dec-RVKR,
an inhibitor of furin and other proprotein convertases (Table 1), partially inhibited CHIKV
6K51-59-specific CD8
+ T cell recognition of infected cells (43 ± 20%; Fig 7). To exclude the pos-
sibility that this inhibition was due to toxic effects on target cells or on VACV replication
rather than to a specific protease block, we performed parallel experiments using the rVACV-
CHIKV-infected target cells with another T cell line. These infected cells were recognized effi-
ciently by the VACV D12I251-259-specific CD8
+ T cell line, and no inhibition was detected
(4 ± 6%; Fig 7). These data indicate that the dec-RVKR-induced inhibition of specific recogni-
tion by CHIKV 6K51-59-restricted CD8
+ T cells was due to protease blockade and not to non-
specific effects. These data indicate that proprotein convertases are involved in the generation
of the CHIKV 6K epitope.
Dipeptidyl-peptidase II (DPPII) is involved in antigen processing and
presentation of the CHIKV 6K51-59 epitope
The inhibitor puromycin (PURO) [37] (Table 1) partially blocked specific recognition of
rVACV-CHIKV-infected target cells by CHIKV 6K51-59-specific CD8
+ T cells (47 ± 21%), but
had no effect on VACV D12I251-259 epitope presentation (4 ± 6%) (Fig 8). PURO is a reversible
inhibitor of the cytosol alanyl aminopeptidase and of lysosomal DPPII. To identify the specific
peptidase involved in CHIKV 6K51-59 peptide processing, we treated rVACV-CHIKV-infected
target cells with additional inhibitors. CHIKV 6K51-59-specific CD8
+ T cell recognition was
unaffected by two distinct inhibitory compounds that block cytosol alanyl aminopeptidase
activity, bestatin (BEST) and EDTA (ethylenediaminetetraacetic acid) (Table 1 and Fig 8),
which excludes this cytosolic enzyme from antigen processing of the CHIKV 6K51-59 epitope.
The antimalarial drug chloroquine (CQ), a lysosomotropic agent that affects DPPII and other
lysosomal enzymes (Table 1), nonetheless blocked recognition of infected cells by CHIKV
Fig 6. Recognition of infected HLA-A*0201+ DC by CHIKV 6K51-59- or VACV D12I251-259-specific CD8
+ T
cells in the presence of general peptidase inhibitors. Mouse HLA-A*0201+ DC infected as in Fig 4 were
treated before ICS assay with the inhibitors E64 (cysteine protease C1), LEU (trypsin-like and cysteine
protease), PEPST (aspartic protease), PHE (metallopeptidase), or PMSF (serine peptidases). CHIKV
6K51-59- or VACV D12I251-259-specific CD8
+ T cell lines were used. The percentage of specific inhibition was
calculated as in Fig 5. Data shown as mean ± SD of three independent experiments.
https://doi.org/10.1371/journal.pntd.0006036.g006
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Fig 7. Recognition of infected HLA-A*0201+ DC by CHIKV 6K51-59- or VACV D12I251-259-specific CD8
+ T
cells in the presence of various protease inhibitors. Mouse HLA-A*0201+ DC infected as in Fig 4 were
treated before ICS assay with protease inhibitors including DANLME (aspartic protease A1 inhibitor), dec-
RVKR (furin and other members of the propotein convertase family), STBI (trypsin, chymotrypsin and
plasmin), Z-LL2 (signal peptide peptidase), or zVAD (caspase). The percentage of specific inhibition was
calculated as in Fig 5. Data shown as mean ± SD of four independent experiments (*** P <0.001 of CHIKV
6K51-59-specific CD8
+ T cells vs. no inhibitor (white asterisks) or VACV D12I251-259 ligand with the inhibitor
(black asterisks)).
https://doi.org/10.1371/journal.pntd.0006036.g007
Fig 8. Effect of several inhibitors on recognition of rVACV-CHIKV-infected cells. Mouse HLA-A*0201+
DC infected as in Fig 4 were treated before ICS assay with inhibitors such as PURO (cytosol alanyl
aminopeptidase and lysosomal DPPII inhibitor), BEST (metallo-aminopeptidases), EDTA (metallopeptidases
and some cysteine proteases), or CQ (lysosomotropic agent). The percentage of specific inhibition was
calculated as in Fig 5. Data shown as mean ± SD of four independent experiments (*** P <0.001, as in Fig 7).
https://doi.org/10.1371/journal.pntd.0006036.g008
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6K51-59-specific CD8
+ T cells (69 ± 19%; Fig 8). These data indicate that DPPII is involved in
CHIKV 6K epitope generation.
Sequential furin-like protease and DPPII activity are necessary for
CHIKV 6K51-59 epitope generation
The inhibition of antigen recognition by dec-RVKR (Fig 7) or PURO (Fig 8) indicated that
furin-like proteases and DPPII peptidase are both involved in antigen presentation of the
CHIKV 6K51-59 epitope. The similar partial inhibition of rVACV-CHIKV-infected cell recog-
nition by both drugs (dec-RVKR, 43 ± 20%; PURO, 47 ± 21%) is compatible with two explana-
tions. The CHIKV 6K51-59 epitope might be processed sequentially by the two proteases.
Alternatively, this epitope could be processed in parallel by proprotein convertases or by
DPPII independently; in this case, both antigen processing pathways would have to be inhib-
ited simultaneously to fully abrogate CHIKV 6K51-59 epitope presentation. To discriminate
between these possibilities, we analyzed the effect on antigen presentation of the combined
inhibitors on rVACV-CHIKV-infected cells. We observed a moderately increased blockage of
presentation in target cells treated simultaneously with PURO and dec-RVKR (66 ± 6%; Fig 9),
comparable and not statistically different to that observed when CQ and dec-RVKR were com-
bined (71 ± 18%; Fig 9) or with CQ alone (69 ± 19%; Fig 8). The inhibitory effect of PURO and
dec-RVKR was CHIKV 6K epitope-specific, as recognition of the VACV D12I251-259 epitope
was not reduced in their presence (Fig 9). These results show that furin-like proteases and
DPPII are found in the same CHIKV 6K51-59 epitope presentation pathway.
Proteasome and ERAP are involved in antigen processing of the CHIKV
6K51-59 epitope
To test whether the classical antigen processing pathway is involved in CHIKV 6K51-59 epitope
generation, we used the proteasome inhibitor lactacystin (LC) [38,39], and leucinthiol (Leu-
Fig 9. Effect of inhibitor combinations in recognition of rVACV-CHIKV-infected DC. Mouse
HLA-A*0201+ DC infected as in Fig 4 were treated before ICS assay with a combination of dec-RVKR and CQ
or PURO. The percentage of specific inhibition was calculated as in Fig 5. Data shown as mean ± SD of three
independent experiments (** P <0.01; * P <0.05, as in Fig 7).
https://doi.org/10.1371/journal.pntd.0006036.g009
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SH), which has activity against ERAP and other metallo-aminopeptidases [40] (Table 1). Both
LC (83 ± 3%) and Leu-SH (91 ± 13%) blocked specific recognition of rVACV-CHIKV-infected
target cells by CHIKV 6K51-59-specific CD8
+ T cells (Fig 10). In contrast, in the same experi-
ment, these drugs had a lesser effect on VACV D12I251-259 epitope presentation (Fig 10).
Differential contribution of peptidases to antigen presentation of the
CHIKV 6K51-59 epitope
CHIKV 6K51-59 epitope presentation to a specific T cell line was partially blocked by dec-
RVKR (43 ± 20%), PURO (47 ± 21%) or both (66 ± 6%) (Figs 7, 8 and 9), whereas CHIKV
6K51-59 recognition by these CD8
+ T cells was strongly inhibited by LC (83 ± 3%) and Leu-SH
(91 ± 13%) (Fig 10). These differences were statistically significant (Table 3), which suggested
Fig 10. Effect of LC and Leu-SH inhibitors on recognition of CHIKV 6K51-59- or VACV D12I251-259 viral
epitopes. Mouse HLA-A*0201+ DC infected as in Fig 4 were treated before ICS assay with LC (proteasome
inhibitor) or Leu-SH (ERAP and other metallo-aminopeptidases). The percentage of specific inhibition was
calculated as in Fig 5. Data shown as mean ± SD of four independent experiments (*** P <0.001; ** P <0.01,
as in Fig 7).
https://doi.org/10.1371/journal.pntd.0006036.g010
Table 3. Statistical analysis of the inhibition values with various inhibitors.
LC Leu-SH dec-RVKR PURO dec-RVKR + PURO
LC - ns a **
b
* *
Leu-SH - *** *** *
dec-RVKR - ns ns
PURO - ns
dec-RVKR + PURO -
a Not significant
b Significant P values: ***, p <0.001; **, p <0.01; *, p <0.05
https://doi.org/10.1371/journal.pntd.0006036.t003
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that the CHIKV 6K51-59 epitope is generated by two distinct pathways, the classical antigen
processing pathway and a second antigen presentation pathway that includes the four prote-
ases (dec-RVKR, PURO, LC and Leu-SH).
Discussion
In this study, we undertook identification of HLA-A0201 epitopes from the CHIKV 6K pro-
tein and explored their antigen presentation pathways. Our results define several CHIKV 6K
protein restricted epitopes, being to our knowledge the first time that epitopes from CHIKV
are defined associated to human MHC class I molecules. Extended epitope prediction using the
SYFPEITHI tool suggests that ligands of this small viral protein could be presented by a notable
proportion of the HLA class I alleles tested (12 of 30; 40%, S1 Table). According to the Immune
Epitope Database (IEDB) population coverage tool (http://tools.iedb.org/population/), these
class I molecules are present in 86% of the human population (S2 Table). The short viral
CHIKV 6K protein is thus of interest for targeting the cellular immune system. Further studies
are needed to analyze cellular immune responses in CHIKV-infected individuals.
Here we identified three HLA-A0201-restricted epitopes in the CHIKV small 6K protein.
Using several protease inhibitors (Table 1), we report that various proteolytic activities (proba-
bly in two distinct antigen processing pathways) are necessary to generate one of these epi-
topes, the CHIKV 6K51-59 epitope. These results are consistent with a model for CHIKV
maturation and processing and, by extrapolation, that of other Alphavirus structural polypro-
teins (Fig 11). Although no furin cleavage motif was found in the 6K protein, 6K51-59 peptide
presentation was dependent on dec-RVKR-sensitive proteases, which indicates that proprotein
convertase activity is needed to generate this epitope. Like other host and viral proteases [41],
furin are involved in processing structural polyproteins in all Alphaviruses to yield the mature
structural proteins that will form the virion. Maturation of the CHIKV structural polyprotein
thus affects antigen processing of the 6K51-59 epitope.
With regard to the CHIKV replication cycle, only limited information can be extrapolated
from comparison between CHIKV structural proteins and those of other Alphaviruses. The
translation order of these Alphavirus polyproteins is capsid, PE2 precursor (that includes enve-
lope glycoproteins E3 and E2, 6K, and envelope protein E1) [41]. Immediately after the ribo-
some starts translation of the PE2 precursor, the capsid protein (whose C-terminal domain
has protease activity) is released in the cytosol by autoproteolysis. The new N terminus of the
polyprotein thus bears a signal sequence for translocation of the PE2 precursor across the ER
membrane. Additional signal sequences in the C terminus of E2 and 6K proteins allow their
translocation to the ER. In the ER, signal peptidase cleavage of the C terminus of both the PE2
precursor and the 6K protein releases three viral protein products (PE2, 6K, and E1). The PE2
precursor and E1 protein remain attached to the membrane by their C terminus, and 6K
remains as a short transmembrane protein. In the Alphavirus Sindbis virus, E1 and PE2 glyco-
proteins form a heterodimer in the ER, and this interaction is sufficient for transport beyond
this organelle [42]. The E1-PE2 heterodimer reaches the trans-Golgi network, but prior to the
cell membrane, CHIKV PE2 is cleaved by furin and other proprotein convertases such as
PC5A, PC5B, and PACE4 to generate the mature E2 and E3 proteins [43]. CHIKV 6K51-59 epi-
tope-dependent presentation by dec-RVKR-sensitive proteases thus indicates that CHIKV
envelope proteins are transported from the ER to the trans-Golgi network as heterotrimers
that also include CHIKV 6K protein, as also described for Semliki Forest virus [44]. In Alpha-
viruses, this cleavage induces conformational changes in E1 and E2 proteins, thus promoting
extensive contacts between these two proteins to yield the spike architecture of activated viral
envelope complex in 1:1 stoichiometry [41]. The role of the E3 structural protein is unclear; E3
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Fig 11. Diversity of proteases and processing pathway involved in CHIKV 6K51-59 epitope presentation. The model shows the
components of the antigen presentation pathway proposed for the CHIKV 6K51-59 epitope. Stop-transfer signals are indicated by
rectangular blocks, and signal sequences by dashed cylinders. Subcellular organelles are shown as colored boxes: cytosol (yellow), ER
(blue), trans-Golgi network (mauve) and lysosomes (green). CHIKV proteins are capsid (CP, maroon), p62 (yellow), 6K (green), E1
(peach), E2 (blue), and E3 (brown). The CHIKV 6K51-59 epitope is depicted in red. The role of the distinct proteases is deduced from
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is associated with virions in Semliki Forest virus [45], but not in other Alphaviruses including
CHIKV [46, 47].
In Semliki Forest and Sindbis viruses, substoichiometric amounts of 6K are incorporated
into the virion [44,48]. Most of this small protein must thus be discarded in the infected cells,
although the fate of the CHIKV 6K protein is nonetheless unclear. As both PURO and CQ
impaired antigen recognition of target cells by CHIKV 6K51-59-specific CD8
+ T cells, the lyso-
somal DPPII must have a role in processing this epitope. This data also indicated that at least a
fraction of the CHIKV 6K protein must be degraded in the lysosomes.
DPPII-processed CHIKV 6K protein or a fragment that includes the viral epitope must be
transported to the cytosol for proteasome processing, as indicated by LC inhibition of the
CHIKV 6K51-59 antigen presentation. How these fragments reached the cytosol remains
unclear, but the proteasome is involved in the generation of some epitopes of the Epstein-Barr
virus (EBV) latent membrane protein 2 (LMP2) transmembrane nucleoprotein, albeit by
uncharacterized mechanisms [49]. Host cell transmembrane protein processing might be
involved in both CHIKV and EBV epitopes [50].
The block in CHIKV 6K51-59-specific recognition by Leu-SH, but not by two drugs that do
not inhibit ERAP activity (the general metalloproteinase inhibitor PHE and the aminoprotease
inhibitor BEST) [51,52], indicates that ERAP or a similar metalloproteinase produces the final
CHIKV 6K51-59 epitope, probably in the ER, after transport of proteasomal products by TAP.
The statistically different percentages of inhibition by LC and Leu-SH inhibitors vs. dec-
RVKR, PURO and CQ drugs also suggest a direct contribution of the classical antigen process-
ing pathway, with proteasome degradation of DRiPs from viral polyprotein followed by ERAP
trimming. The relative contribution of both pathways to antigen presentation was quantified
using the same percentage of inhibition from one-third to half by the classical antigen process-
ing pathway and half to two-thirds by the circular antigen presentation pathway. Our results
show a broad diversity of proteases involved in a complex antigen presentation pathway to
yield the viral CHIKV 6K epitope.
In addition to proteasome and ERAP, several proteases are implicated in processing endog-
enously synthesized HLA class I antigens (reviewed in [19]). Many proteases included here,
such as signal peptidase [53,54], furin [55,56], and uncharacterized lysosomal CQ-sensitive
enzymes [57,58], have been linked independently to the processing of several epitopes,
although sequential activity of these peptidases to generate a specific HLA class I epitope has
not been described. These proteases and the supplementary involvement of DPPII in CHIKV
6K51-59 antigen presentation define the most complex antigen processing and presentation
pathway reported to date; this route begins in the ER and includes the trans-Golgi network,
lysosomes, retrograde transport to cytosol, and ER re-entry.
Lastly, the results reported here also have implications for analysis of the cellular immune
response. Only proteasome and ERAP, but not other protease inhibitors, are generally used to
analyze antigen presentation of different HLA class I ligands or epitopes. Inhibition is nor-
mally sufficient to formally assign presentation of an epitope to the classical antigen processing
pathway, excluding additional protease activities (Fig 10). In addition to the Alphavirus genus
and the Togaviridae family, however, many viruses of different families and orders use host
proteases from distinct subcellular locations to generate mature envelope and even nuclear
proteins. In other viral epitopes, it would thus not be unexpected to find complex antigenic
processing and presentation pathways similar to those reported here, if the antiviral cellular
CD8+ T cell sensitivity to the various inhibitors, except for the signal peptidase, whose role was described in the generation of the
Alphavirus 6K protein [59].
https://doi.org/10.1371/journal.pntd.0006036.g011
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immune response was analyzed in depth with a broad spectrum of protease inhibitors as was
carry out in the current investigation.
In conclusion, the results of the present report highlight the diversity of peptidases involved
in HLA class I antigen presentation and expose the complexity of antigen processing pathways,
as represented by the CHIKV 6K protein. Definition of the importance of this epitope in natu-
ral infection nonetheless awaits studies in CHIKV-infected individuals. This process could
have broad implications when applied to other viral proteins.
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